NASDAQ: SMMT
Summit Therapeutics Inc Stock Ownership - Who owns Summit Therapeutics?

Insider buying vs selling

Have Summit Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Manmeet Singh SoniCFO;COO2026-11-16100,000$1.37
$137.00kBuy
Mahkam ZanganehCEO2026-11-16500,000$1.06
$530.00kBuy
Robert W. DugganCEO2026-11-16500,000$1.06
$530.00kBuy
Robert W. DugganCo-Chief Executive Officer2026-06-123,810,000$13.12
$49.99MBuy
Mahkam ZanganehCo-Chief Executive Officer2026-06-123,810,000$13.12
$49.99MBuy
Manmeet Singh SoniCOO and CFO2026-06-0425,000$14.43
$360.75kBuy
Manmeet Singh SoniCOO and CFO2026-06-0425,000$14.46
$361.50kBuy
Robert W. DugganCo-Chief Executive Officer2026-06-04100,000$14.60
$1.46MBuy
Mahkam ZanganehCo-Chief Executive Officer2026-06-04100,000$14.60
$1.46MBuy

1 of 1

SMMT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SMMT insiders and whales buy or sell their stock.

SMMT Shareholders

What type of owners hold Summit Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Mahkam Zanganeh156.91%1,254,881,831$13.39BInsider
Robert W. Duggan80.85%646,571,059$6.90BInsider
Yu Xia4.01%32,057,147$342.05MInsider
Maky Zanganeh1.87%14,915,775$159.15MInsider
Manmeet Singh Soni0.40%3,224,375$34.40MInsider
Ankur Dhingra0.05%394,485$4.21MInsider
Bhaskar Anand0.03%261,047$2.79MInsider
Jeff Huber0.01%56,052$598.07kInsider
Baker Bros Advisors LP0.00%32,786$349.83kInstitution
Jos Houbiers0.00%15,512$165.51kInsider

1 of 3

SMMT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SMMT0.01%99.99%Net BuyingNet Buying
PTGX0.12%22.34%Net SellingNet Selling
PRAX0.12%50.22%Net Selling
RYTM0.11%13.44%Net SellingNet Selling
MDGL0.03%99.97%Net BuyingNet Buying

Summit Therapeutics Stock Ownership FAQ

Who owns Summit Therapeutics?

Summit Therapeutics (NASDAQ: SMMT) is owned by 0.02% institutional shareholders, 244.12% Summit Therapeutics insiders, and 0.00% retail investors. Mahkam Zanganeh is the largest individual Summit Therapeutics shareholder, owning 1.25B shares representing 156.91% of the company. Mahkam Zanganeh's Summit Therapeutics shares are currently valued at $13.18B.

If you're new to stock investing, here's how to buy Summit Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.